A conversation with James Amihood, CEO at Digital Telehealth Company: Cardiocol

cardiocol forms a more age-friendly method for mass prevention of health disasters in large risk groups by expanding and complementing the gold standard screening and surveillance methods.

The company’s software applications continuously analyze daily speech samples through commonly used voice interfaces to identify and track its proprietary vocal biomarkers for at-risk, treatable, and “silent” health conditions.

Our first voice app focuses on early detection and improved tracking of the most common and dangerous cardiac arrhythmias, most notably atrial fibrillation (AF) – a leading cause of sudden strokes and other life-changing conditions.

Timely detection and treatment of arrhythmias such as atrial fibrillation can prevent over 70% of atrial fibrillation-related strokes and other chronic, costly complications.


How did Cardiocol come about?

The mother of one of the founders had developed atrial fibrillation (AF), which eventually led to an ischemic stroke.

She underwent cardiac ablation, took her anticoagulant medication daily, and used an EKG (electrocardiogram) machine as a spot check to monitor her condition when she experienced symptoms. Despite these steps, the stroke she suffered was caused by asymptomatic (“silent”) atrial fibrillation over a few days when she was fine and when she forgot to take her anticoagulants.

During this time, her son was concerned about her “silent” risk of stroke and frustrated by the lack of ongoing monitoring methods that suited his mother’s (age) preferences.

In search of a more age-friendly method, suitable for systematic and frequent monitoring, he found publications demonstrating the correlation between heartbeats and voice (chaotic heart rhythm indicates atrial fibrillation).

With his extensive background in healthcare technology, synergistic co-founders he worked with from the telecommunications and speech analytics industries, and a vision to develop a more age-friendly, deviceless and cost-effective speech-based method for prolonged telemonitoring of such silent and key health risks in the growing population older adult – Cardiokol was founded.

How has the company performed during the pandemic?

While the company’s clinical trials slowed sharply during the crisis, the need and adoption of telemedicine services has rapidly increased.

Recent growth in this sector has highlighted the gaps in access for certain population groups – low-income patients and patients with limited experience with or access to technology (e.g. older adults).

Luckily, Cardiokol bridges these gaps by offering intuitive and affordable telemedicine solutions.

What can we expect from Cardiokol in the future?

The company strives to scale its software voice apps to smart speakers and phones, landlines, call centers and telecom networks to continuously better serve vulnerable and underreached populations (e.g. over 65 years old) and ultimately reduce the immense health -socioeconomic burdens associated with preventable life-changing health events.

https://techround.co.uk/interviews/a-chat-with-james-amihood-cardiokol/?utm_source=rss&utm_medium=rss&utm_campaign=a-chat-with-james-amihood-cardiokol A conversation with James Amihood, CEO at Digital Telehealth Company: Cardiocol

Fry Electronics Team

Fry Electronics.com is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – admin@fry-electronics.com. The content will be deleted within 24 hours.

Related Articles

Back to top button